
Analy Mora
@analymorac
🩺
ID: 1366473276797505536
01-03-2021 19:39:59
99 Tweet
211 Followers
424 Following

Rethinking transfusion premedication in this issue's #TWDFNR by Ming Y Lim 明林 et al #VisualAbstract fal.cn/3bSaq



Our 📄 about the prevalence and impact of tumor lysis syndrome in a cohort of adult ALL patients. Thanks to my mentor Roberta Demichelis and the team Fernando Gil-Lopez Analy Mora #TLS #AcuteLeukemia karger.com/aha/article-ab…

Come visit Analy Mora at poster #3956 for our data regarding H. pylori screening in ITP patients at a high-prevalence country #ASH #ASH2023


Is it safe to administer rituximab in Ph+ ALL? Come visit our poster #4204, a collaboration of five centers in Mexico Analy Mora Fausto A. Rios Olais Roberta Demichelis #ASH #ASH2023


I can’t thank you enough for all your support. I’m grateful to have had the opportunity of working with you. Roberta Demichelis







So glad to see the results of PI regimens implementation in our country by Roberta Demichelis. Important data that encourages ALL research in LATAM Society of Hematologic Oncology (SOHO).


The Mexican contingent at #ASH24 Fellows from INCMNSZ (Mexico city) HU UANL (Monterrey)… and two young-looking albeit wise junior faculty 😉Roberta Demichelis


CONGRESS | #ASH24 | POSTER Fausto A Rios-Olais Fausto A. Rios Olais INCMNSZ shares findings from a study examining the relationship between metabolic complications and asparaginase-containing pediatric-inspired regimens in adult patients with ALL (N = 92). Liver steatosis was associated



1/ 📢 Let’s dive into a crucial topic in #Hematology: How do adult regimens compare with pediatric-inspired regimens (PIRs) for Philadelphia-negative ALL? Our study from Mexico offers some insights #ALL Roberta Demichelis Fausto A. Rios Olais Juan Rangel MD Analy Mora onlinelibrary.wiley.com/doi/10.1111/ej…



📢 Body composition in adult ALL 📊 In our study published at ESPEN, CT-assessed muscle mass & adiposity (visceral & subcutaneous) were linked to worse survival & more infections. clinicalnutritionespen.com/article/S2405-… Roberta Demichelis Fernando Gil-Lopez Analy Mora Jessica Zalapa

📊 How many patients with lymphoma or myeloma in the US actually benefit from bispecific antibodies? In our Blood Advances letter, we estimate eligibility and response under current FDA labels—and why real-world benefit may be limited. Talal Hilal 🩺 ashpublications.org/bloodadvances/…